Disclosures: Yang Ling : Nothing to Disclose, Jiaqi Gu: Nothing to Disclose, Yi Xiang: Nothing to Disclose, Jitao Wang: Nothing to Disclose, Deqiang Ma: Nothing to Disclose, He Zhu: Nothing to Disclose, Tianyu Liu: Nothing to Disclose, Chunlong Li: Nothing to Disclose, Qi Zhang: Nothing to Disclose, Jiahao Han: Nothing to Disclose, Deping Ding: Nothing to Disclose, Wei Wang: Nothing to Disclose, Qianlong Li: Nothing to Disclose, Haoguang Wan: Nothing to Disclose, Tianqi Wang: Nothing to Disclose, Xiaolong Qi: Nothing to Disclose 2137 SAFETY AND TOLERABILITY OF SIMVASTATIN 40MG IN A PROSPECTIVE MULTICENTER RANDOMIZED BLINDED CONTROLLED TRIAL OF CHILD-TURCOTTE-PUGH A PATIENTS WITH CLINICALLY SIGNIFICANT PORTAL HYPERTENSION David Kaplan 1 Rajni Mehta 2 Alexander Burdzy 3 Sofia Lizza 3 Gyorgy Baffy 4 Ruben Hernaez 5 Alexander Monto 6 George Ioannou 7 Kristel Hunt 8 Tae Hoon Lee 8 Jasmohan Bajaj 9 Craig McClain 10 Ayse Aytaman 11 Tamar Taddei 12 , 1 University of Pennsylvania, 2 VA Connecticut Health Care System, 3 Cpl Michael J Crescenz VA Medical Center, 4 VA Boston Healthcare System, 5 Baylor College of Medicine, 6 University of California, San Francisco, 7 University of Washington Medical Center, 8 Bronx VA Medical Center, 9 Virginia Commonwealth University, 10 University of Louisville, 11 VA NY Harbor Healthcare System Brooklyn Campus, 12 Yale University Background: HMG-CoA reductase inhibitors (statins) exert pleiotropic effects that reduce inflammation and fibrosis and improve vascular reactivity
The documented example is the Tesamorelin + Ipamorelin protocol
Data obtained from experimental studies
Body-weight endpoints Investigated in phase 2 obesity trials for modest weight reduction independent of diabetes status
Boost Gluta Glutathione L-Cysteine, L-Glutamine, Glycine Alpha Lipoic Acid 2
